Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 3/20 | 0.41 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.39 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27290487 | 0.85 | MAPT (0.38) | ALDH1A1MAPTLMNATSHRCYP3A4 | |
| SCHEMBL27525587 | 0.85 | MAPT (0.65) | ALDH1A1MAPTLMNATSHRCYP3A4 | |
| SCHEMBL10837142 | 0.84 | MAPT (0.48) | ALDH1A1MAPTLMNATSHRCYP3A4 | |
| SCHEMBL27471028 | 0.84 | MAPT (0.62) | ALDH1A1MAPTLMNATSHRCYP3A4 | |
| SCHEMBL10835316 | 0.83 | TSHR (0.46) | ALDH1A1MAPTLMNATSHRCYP3A4 | |
| SCHEMBL10835334 | 0.81 | MAPT (0.46) | ALDH1A1MAPTLMNATSHRCYP3A4 | |
| SCHEMBL9772007 | 0.81 | ALDH1A1 (0.43) | ALDH1A1MAPTLMNATSHRCYP3A4 | |
| SCHEMBL9771985 | 0.81 | ALDH1A1 (0.43) | ALDH1A1MAPTLMNATSHRCYP3A4 | |
| SCHEMBL3031373 | 0.79 | KDM4E (0.58) | ALDH1A1MAPTLMNAKDM4EDUSP3 | |
| SCHEMBL30366092 | 0.79 | MAPT (0.52) | ALDH1A1MAPTLMNATSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3255031-B1 | COMPOUND, AND SEPARATION METHOD, SYNTHESIS METHOD AND USE THEREOF | BEIJING PEKING UNIV WBL BIOTECH CO LTD (CN) | 2021-09-29 | — | — | EP | claimed |
| US-8309545-B2 | Benzofuran potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-11-13 | — | — | US | disclosed |
| US-8217189-B2 | Chromenone potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-07-10 | — | — | US | disclosed |
| US-20100087430-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-04-08 | — | — | US | disclosed |
| US-20090298931-A1 | NOVEL CHROMENONE POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2009-12-03 | — | — | US | disclosed |
| WO-2008040057-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2008-04-10 | — | — | WO | disclosed |
| US-5608059-A | BIPYRIDINIUMS THAT CAN BE INCORPORATED IN ELECTROCHEMICAL OR OPTICAL SENSORS FOR ANION DETERMINATION | EASTMAN KODAK COMPANY (US) | 1997-03-04 | — | — | US | disclosed |
| EP-0412487-B1 | Process for the preparation of castanospermine esters | MERRELL DOW PHARMA (US) | 1994-12-28 | — | — | EP | disclosed |
| EP-0325268-B1 | 1,4-DISUBSTITUTED-PIPERIDINYL COMPOUNDS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-06-02 | — | — | EP | disclosed |
| US-5162342-A | USE OF 1,4-DISUBSTITUTED-PIPERIDINYL COMPOUNDS FOR ANALGESIA AND MUSCLE RELAXATION | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-11-10 | — | — | US | disclosed |
| US-5064838-A | 1,4-DISUBSTITUTED-PIPERIDINYL COMPOUNDS AS PAIN RELIEVERS | MERRELL DOW PHARMACEUTICALS (US) | 1991-11-12 | — | — | US | disclosed |
| EP-0412487-A2 | Process for the preparation of castanospermine esters | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-02-13 | — | — | EP | disclosed |
| US-4970317-A | Process for the preparation of castanospermine esters | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-11-13 | — | — | US | disclosed |
| EP-0325268-A1 | 1,4-Disubstituted-piperidinyl compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087430-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNA3, KCNB1, KCNK3 | ALDH1A1 2900/4885MAPT 2351/4885LMNA 1489/4885 |
| US-20090298931-A1 | NOVEL CHROMENONE POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNK3, KCNA3, KCND3 | ALDH1A1 3858/4885MAPT 2844/4885LMNA 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.